DNA甲基化与结直肠癌的预后及治疗进展(5)
[29] Plumb JA，Strathdee G，Shddan J，et al.Reversal dmgresistance in human tumor xenografts by 2'-deoxy-5-azaeytidine-induced demethylation of the hMLHl gene promoter[J].Cancer Res，2000，60：6039-6044.
[30] Matthias Schaefer，Sabine Hagmann，Katharina Hanna，et al.Azacytidine Inhibits RNA methylation at DNMT2 target sites in human cancer cell lines[J].Cancer Res，2009，69：8127-8132.
[31] Davis AJ，Gelmon KA，Siu LL，et al.Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks[J].Invest New Drugs，2003，21：85-89.
[32] Winquist E，Knox J，Ayoub JP，et al.PhaseⅡ trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma：a national cancer institute of canada clinical trials group investigational new drug study[J].Invest New Drugs，2006，24：159-167.
[33] Stephenson J，Amato RJ，Hotte S，et al.A dose and schedule optimizing evaluation of MG98 given as either a 2 hour IV infusion twice weekly or as a 7 day continuous infusion in combination with interferon alpha (INF)in nephrectomized patients(pts)with advanced renal cell carcinoma(RCC)[J].J Clin Oncol，2006，24(18 suppl)：641s(Abstract 14557).
[34] Sobin LH，Gospodarowicz MK，Wittekind C.TNM classification of malignant tumors.7th[M].Hoboken：John Wiley &Sons，2009：163.
(收稿日期：2012-10-15), 百拇医药(王春晓?罗开元)
[30] Matthias Schaefer，Sabine Hagmann，Katharina Hanna，et al.Azacytidine Inhibits RNA methylation at DNMT2 target sites in human cancer cell lines[J].Cancer Res，2009，69：8127-8132.
[31] Davis AJ，Gelmon KA，Siu LL，et al.Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks[J].Invest New Drugs，2003，21：85-89.
[32] Winquist E，Knox J，Ayoub JP，et al.PhaseⅡ trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma：a national cancer institute of canada clinical trials group investigational new drug study[J].Invest New Drugs，2006，24：159-167.
[33] Stephenson J，Amato RJ，Hotte S，et al.A dose and schedule optimizing evaluation of MG98 given as either a 2 hour IV infusion twice weekly or as a 7 day continuous infusion in combination with interferon alpha (INF)in nephrectomized patients(pts)with advanced renal cell carcinoma(RCC)[J].J Clin Oncol，2006，24(18 suppl)：641s(Abstract 14557).
[34] Sobin LH，Gospodarowicz MK，Wittekind C.TNM classification of malignant tumors.7th[M].Hoboken：John Wiley &Sons，2009：163.
(收稿日期：2012-10-15), 百拇医药(王春晓?罗开元)